Oliver brings investment experience in biology and venture capital as an investment director at Future Planet Capital and the UK Innovation & Science Seed Fund, alongside multiple board observer and member roles.
Northern Gritstone led the seed round to support the rollout of the firm's crop technology across major food species.
"Food security and sustainability are two of our most pressing global challenges, and issues that we must be prepared to face today to ensure we are ready to meet the needs of tomorrow. We developed MOSS with those challenges in mind – a unique crop engineering solution capable of streamlining regulatory pathways and generating crops with new, enhanced, and more carbon-conscious traits. Thank you to our investors, whose support reaffirms our belief in the potential of MOSS to bring about a new frontier in crop technology."
The round was co-led by East X Ventures and Sure Valley Ventures to support the development of hybrid artificial intelligence for high-stakes environments.
The equity round was led by Green Angel Ventures and the Development Bank of Wales.
"Current carbon fibre material formats are expensive, hard to form into shape and highly wasteful with poor recycling routes. It is more expensive than aluminium and has a much higher footprint CO2e than steel, yet more than 90% end up in landfill."
The seed financing was co-led by UKI2S and Cambridge Enterprise Ventures to support the commercial deployment of photonic chip designs.
"The team has spent the past few years building and experimentally validating our design technology – it’s exciting to have the resources to begin deploying it to solve real industry problems."
Calculus Capital led the financing round alongside several institutional investors to support platform development and pipeline progression.
"GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments."
